A naukri.com initiative
Bioengineer
1w
397
Image Credit: Bioengineer
HHS Panel Advises Statin Use for Cardiovascular Risk Management in Adults with HIV
- A collaboration between HHS Panel for the Use of Antiretroviral Agents in HIV, ACC, AHA, and HIVMA recommends statin therapy for cardiovascular risk management in adults with HIV.
- The guidelines stem from the REPRIEVE trial, which demonstrated a 36% MACE reduction with pitavastatin in people with HIV at low to intermediate ASCVD risk.
- Statin therapy initiation is suggested for HIV individuals aged 40-75 with ASCVD 10-year risk score of 5% or higher.
- For those under 40, a personalized approach considering familial predispositions and risk factors is advised.
- Preferred statins include pitavastatin, atorvastatin, and rosuvastatin due to their pharmacokinetic profiles and minimal drug interactions with antiretrovirals.
- Ongoing research is highlighted to refine cardiovascular risk prediction models specific to the HIV population.
- Collaboration among specialists is emphasized for comprehensive assessment and management of cardiovascular risks in PWH.
- The integration of statin therapy into routine HIV care is viewed as a potential strategy to reduce cardiovascular morbidity and mortality in this population.
- Clinician-patient shared decision-making is encouraged to tailor treatment regimens to individual needs and optimize long-term outcomes.
- These evidence-based recommendations mark a crucial step in addressing the heightened cardiovascular risk in individuals living with HIV.
Read Full Article
23 Likes
For uninterrupted reading, download the app